Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus FEXINIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE AND PROGUANIL HYDROCHLORIDE versus FEXINIDAZOLE.
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE vs FEXINIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a mitochondrial electron transport inhibitor that selectively targets the cytochrome bc1 complex, disrupting pyrimidine synthesis in Plasmodium. Proguanil hydrochloride is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. The combination synergistically inhibits plasmodial replication.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
250 mg atovaquone/100 mg proguanil hydrochloride (1 tablet) orally once daily for prophylaxis; 4 tablets (1000 mg/400 mg) orally once daily for 3 consecutive days for treatment.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
None Documented
None Documented
Atovaquone: terminal half-life 2-3 days (67-83 hours); prolonged to 4-5 days in malaria due to drug accumulation. Proguanil: terminal half-life 12-21 hours; cycloguanil 14-21 hours.
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Atovaquone: >94% excreted unchanged in feces via biliary elimination; renal excretion minimal (<1%). Proguanil: ~40-60% excreted renally as unchanged drug and metabolites (primarily cycloguanil and 4-chlorophenylbiguanide).
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Category A/B
Category C
Antiprotozoal
Antiprotozoal